ATLyphe AG

ATLyphe emerges from a shared effort between ETH and UZH, driven by the mission to enhance therapy and cure for AML patients. Currently, HSCT is the only curative interventions, yet, largely due to the conditioning process, it often fails to keep the curative promise. Our focus is on pioneering a safer and more precise conditioning approach that unlocks the full curative potential of HSCT and gives new hope to AML patients. We designed ALY117, a bispecific T cell engager particularly suited to treat diseases residing in the bone marrow. ALY117 can be used as a conditioning agent that removes any residual leukemic cell, preventing relapse, and stem cells, preparing the patient for the transplantation. Together, ALY117 makes the process more bearable and increases the changes of survival.